In the ICON7 trial evaluating bevacizumab in advanced ovarian cancer, the addition of bevacizumab to carboplatin-paclitaxel showed the greatest overall survival benefit in which subgroup?
- A High-risk advanced disease (FIGO IIIB–IV or suboptimally debulked IIIA) ✓
- B Early-stage (FIGO I–IIA) fully resected disease
- C BRCA-mutated patients regardless of stage
- D Platinum-resistant recurrent ovarian cancer
Correct answer: A. High-risk advanced disease (FIGO IIIB–IV or suboptimally debulked IIIA)
Explanation
In the ICON7 trial, bevacizumab added to carboplatin-paclitaxel and continued as maintenance showed a statistically significant overall survival benefit specifically in the high-risk subgroup (FIGO stage IIIB–IV or suboptimally debulked IIIA), not in the overall population. Early-stage disease did not benefit. BRCA mutation status was not the defining criterion in ICON7 (PARP inhibitors are the therapy relevant to BRCA).
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.